Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment.

Abstract

The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in the treatment of advanced non-small-cell lung cancer (NSCLC), but the median survival of patients is short. Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. The first patient was alive at 8 years with alternative conventional chemotherapy and gefitinib, and the second patient was alive at long-term follow-up with conventional chemotherapy and gefitinib or erlotinib. Gefitinib, erlotinib, and conventional chemotherapy can be combined for satisfactory therapy for NSCLC.

• Authors: M X Zhang, W Tan, R X Zhang, Y L Tian, H M Gao, Z Gao, N Zhang, J Q Zhao, Y F Jia, Y S Wang
• Journal: Genetics and molecular research : GMR (Genet Mol Res) Vol. 13 Issue 4 Pg. 8657-60 (Oct 27 2014) ISSN: 1676-5680 [Electronic] Brazil
• PMID: 25366755 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Quinazolines
• Erlotinib Hydrochloride
• ErbB Receptors
• Gefitinib

Topics

• Aged
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Disease-Free Survival
• ErbB Receptors (antagonists & inhibitors)
• Erlotinib Hydrochloride
• Female
• Gefitinib
• Humans
• Lung Neoplasms (drug therapy)
• Quinazolines (therapeutic use)